Real-world cabazitaxel safety: The Italian early-access program in metastatic castration-resistant prostate cancer

Sergio Bracarda, Angela Gernone, Donatello Gasparro, Paolo Marchetti, Monica Ronzoni, Roberto Bortolus, Lucia Fratino, Umberto Basso, Roberto Mazzanti, Caterina Messina, Marcello Tucci, Francesco Boccardo, Giacomo Cartenì, Carmine Pinto, Giuseppe Fornarini, Rodolfo Mattioli, Giuseppe Procopio, Vincenzo Chiuri, Tiziana Scotto, Davide DondiGiuseppe Di Lorenzo

Research output: Contribution to journalArticle

Abstract

Aim: Cabazitaxel is a novel taxane that is approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. A global early-access program was initiated in order to provide early access to cabazitaxel in docetaxel-pretreated patients and to obtain real-world data. Patients & methods: We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218 patients receiving cabazitaxel 25 mg/m2 every 3 weeks plus prednisolone 10 mg/day, until disease progression, unacceptable toxicity, investigator's decision or death. Results: Patients completing treatment received a median of six cabazitaxel cycles. The most common grade 3/4 adverse events were neutropenia (33.9%), leukopenia (15.6%), anemia (6%) and asthenia (6%). No peripheral neuropathy or nail disorders were observed. Conclusion: These results confirm that cabazitaxel has a manageable safety profile in daily clinical practice and support its use in patients with prostate cancer who progress during or after a docetaxel-based therapy.

Original languageEnglish
Pages (from-to)975-983
Number of pages9
JournalFuture Oncology
Volume10
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Castration
Prostatic Neoplasms
docetaxel
Safety
Prednisone
Asthenia
Mitoxantrone
Leukopenia
Peripheral Nervous System Diseases
Nails
Prednisolone
Neutropenia
Disease Progression
cabazitaxel
Anemia
Research Personnel
Survival
Therapeutics

Keywords

  • cabazitaxel
  • castrate resistant
  • docetaxel
  • prostate cancer
  • safety
  • taxane

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Real-world cabazitaxel safety : The Italian early-access program in metastatic castration-resistant prostate cancer. / Bracarda, Sergio; Gernone, Angela; Gasparro, Donatello; Marchetti, Paolo; Ronzoni, Monica; Bortolus, Roberto; Fratino, Lucia; Basso, Umberto; Mazzanti, Roberto; Messina, Caterina; Tucci, Marcello; Boccardo, Francesco; Cartenì, Giacomo; Pinto, Carmine; Fornarini, Giuseppe; Mattioli, Rodolfo; Procopio, Giuseppe; Chiuri, Vincenzo; Scotto, Tiziana; Dondi, Davide; Di Lorenzo, Giuseppe.

In: Future Oncology, Vol. 10, No. 6, 2014, p. 975-983.

Research output: Contribution to journalArticle

Bracarda, S, Gernone, A, Gasparro, D, Marchetti, P, Ronzoni, M, Bortolus, R, Fratino, L, Basso, U, Mazzanti, R, Messina, C, Tucci, M, Boccardo, F, Cartenì, G, Pinto, C, Fornarini, G, Mattioli, R, Procopio, G, Chiuri, V, Scotto, T, Dondi, D & Di Lorenzo, G 2014, 'Real-world cabazitaxel safety: The Italian early-access program in metastatic castration-resistant prostate cancer', Future Oncology, vol. 10, no. 6, pp. 975-983. https://doi.org/10.2217/fon.13.256
Bracarda, Sergio ; Gernone, Angela ; Gasparro, Donatello ; Marchetti, Paolo ; Ronzoni, Monica ; Bortolus, Roberto ; Fratino, Lucia ; Basso, Umberto ; Mazzanti, Roberto ; Messina, Caterina ; Tucci, Marcello ; Boccardo, Francesco ; Cartenì, Giacomo ; Pinto, Carmine ; Fornarini, Giuseppe ; Mattioli, Rodolfo ; Procopio, Giuseppe ; Chiuri, Vincenzo ; Scotto, Tiziana ; Dondi, Davide ; Di Lorenzo, Giuseppe. / Real-world cabazitaxel safety : The Italian early-access program in metastatic castration-resistant prostate cancer. In: Future Oncology. 2014 ; Vol. 10, No. 6. pp. 975-983.
@article{bbcd2c76750b49599b99008e9af377f9,
title = "Real-world cabazitaxel safety: The Italian early-access program in metastatic castration-resistant prostate cancer",
abstract = "Aim: Cabazitaxel is a novel taxane that is approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. A global early-access program was initiated in order to provide early access to cabazitaxel in docetaxel-pretreated patients and to obtain real-world data. Patients & methods: We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218 patients receiving cabazitaxel 25 mg/m2 every 3 weeks plus prednisolone 10 mg/day, until disease progression, unacceptable toxicity, investigator's decision or death. Results: Patients completing treatment received a median of six cabazitaxel cycles. The most common grade 3/4 adverse events were neutropenia (33.9{\%}), leukopenia (15.6{\%}), anemia (6{\%}) and asthenia (6{\%}). No peripheral neuropathy or nail disorders were observed. Conclusion: These results confirm that cabazitaxel has a manageable safety profile in daily clinical practice and support its use in patients with prostate cancer who progress during or after a docetaxel-based therapy.",
keywords = "cabazitaxel, castrate resistant, docetaxel, prostate cancer, safety, taxane",
author = "Sergio Bracarda and Angela Gernone and Donatello Gasparro and Paolo Marchetti and Monica Ronzoni and Roberto Bortolus and Lucia Fratino and Umberto Basso and Roberto Mazzanti and Caterina Messina and Marcello Tucci and Francesco Boccardo and Giacomo Carten{\`i} and Carmine Pinto and Giuseppe Fornarini and Rodolfo Mattioli and Giuseppe Procopio and Vincenzo Chiuri and Tiziana Scotto and Davide Dondi and {Di Lorenzo}, Giuseppe",
year = "2014",
doi = "10.2217/fon.13.256",
language = "English",
volume = "10",
pages = "975--983",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Real-world cabazitaxel safety

T2 - The Italian early-access program in metastatic castration-resistant prostate cancer

AU - Bracarda, Sergio

AU - Gernone, Angela

AU - Gasparro, Donatello

AU - Marchetti, Paolo

AU - Ronzoni, Monica

AU - Bortolus, Roberto

AU - Fratino, Lucia

AU - Basso, Umberto

AU - Mazzanti, Roberto

AU - Messina, Caterina

AU - Tucci, Marcello

AU - Boccardo, Francesco

AU - Cartenì, Giacomo

AU - Pinto, Carmine

AU - Fornarini, Giuseppe

AU - Mattioli, Rodolfo

AU - Procopio, Giuseppe

AU - Chiuri, Vincenzo

AU - Scotto, Tiziana

AU - Dondi, Davide

AU - Di Lorenzo, Giuseppe

PY - 2014

Y1 - 2014

N2 - Aim: Cabazitaxel is a novel taxane that is approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. A global early-access program was initiated in order to provide early access to cabazitaxel in docetaxel-pretreated patients and to obtain real-world data. Patients & methods: We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218 patients receiving cabazitaxel 25 mg/m2 every 3 weeks plus prednisolone 10 mg/day, until disease progression, unacceptable toxicity, investigator's decision or death. Results: Patients completing treatment received a median of six cabazitaxel cycles. The most common grade 3/4 adverse events were neutropenia (33.9%), leukopenia (15.6%), anemia (6%) and asthenia (6%). No peripheral neuropathy or nail disorders were observed. Conclusion: These results confirm that cabazitaxel has a manageable safety profile in daily clinical practice and support its use in patients with prostate cancer who progress during or after a docetaxel-based therapy.

AB - Aim: Cabazitaxel is a novel taxane that is approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. A global early-access program was initiated in order to provide early access to cabazitaxel in docetaxel-pretreated patients and to obtain real-world data. Patients & methods: We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218 patients receiving cabazitaxel 25 mg/m2 every 3 weeks plus prednisolone 10 mg/day, until disease progression, unacceptable toxicity, investigator's decision or death. Results: Patients completing treatment received a median of six cabazitaxel cycles. The most common grade 3/4 adverse events were neutropenia (33.9%), leukopenia (15.6%), anemia (6%) and asthenia (6%). No peripheral neuropathy or nail disorders were observed. Conclusion: These results confirm that cabazitaxel has a manageable safety profile in daily clinical practice and support its use in patients with prostate cancer who progress during or after a docetaxel-based therapy.

KW - cabazitaxel

KW - castrate resistant

KW - docetaxel

KW - prostate cancer

KW - safety

KW - taxane

UR - http://www.scopus.com/inward/record.url?scp=84903150063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903150063&partnerID=8YFLogxK

U2 - 10.2217/fon.13.256

DO - 10.2217/fon.13.256

M3 - Article

C2 - 24295376

AN - SCOPUS:84903150063

VL - 10

SP - 975

EP - 983

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 6

ER -